Skip to main content

Table 2 Hazard ratio for all-cause mortality among patients with newly diagnosed hypertension

From: Disparities in socioeconomic status and neighborhood characteristics affect all-cause mortality in patients with newly diagnosed hypertension in Korea: a nationwide cohort study, 2002–2013

 

Unadjusted

Adjusted

Characteristics

HR

95% CI

HR

95% CI

Age

    

 20 ~ 49

1.00

 

1.00

 

 50 ~ 59

1.88

(1.65–2.15)

2.35

(2.06–2.68)

 60 ~ 69

4.41

(3.93–4.96)

4.85

(4.31–5.46)

 ≥70

15.49

(13.87–17.30)

12.60

(11.26–14.11)

Sex

    

 Male

1.10

(1.05–1.15)

1.56

(1.49–1.63)

 Female

1.00

 

1.00

 

Health insurance type

    

 National health insurance

1.00

 

1.00

 

 Medical aid

1.58

(1.40–1.79)

0.80

(0.70–0.91)

Income, N (%)

    

 Low (≤20th percentile)

1.27

(1.19–1.35)

1.25

(1.17–1.34)

 Middle (21st–80th percentile)

0.95

(0.90–1.00)

1.16

(1.10–1.22)

 High (≥81st percentile)

1.00

 

1.00

 

Carstairs index, N (%)

    

 Disadvantaged neighborhood (below median)

1.03

(0.95–1.10)

1.08

(1.02–1.15)

 Advantaged neighborhood (above median)

1.00

 

1.00

 

Residential area

    

 Metropolitan

1.00

 

1.00

 

 Urban

1.11

(1.06–1.17)

1.04

(0.98–1.11)

 Rural

1.47

(1.38–1.57)

1.14

(1.05–1.24)

Charlson comorbidity indexa

    

 0–1

1.00

 

1.00

 

 2

1.46

(1.37–1.55)

1.25

(1.18–1.34)

 3

2.15

(2.01–2.30)

1.67

(1.56–1.79)

 ≥4

4.41

(4.17–4.66)

2.69

(2.54–2.85)

Number of risk factors

    

 None

1.00

 

1.00

 

 with diabetes or dyslipidemia

0.57

(0.54–0.60)

0.63

(0.60–0.66)

 with diabetes and dyslipidemia

0.26

(0.23–0.29)

0.36

(0.33–0.40)

 Disability

    

 Normal

1.00

 

1.00

 

 Mild disability

1.47

(1.36–1.59)

1.11

(1.03–1.21)

 Severe disability

3.00

(2.77–3.27)

1.44

(1.33–1.57)

Health screening during follow-up period

    

 1

1.00

 

1.00

 

 2

0.31

(0.29–0.34)

0.39

(0.36–0.42)

 ≥3

0.11

(0.10–0.12)

0.17

(0.16–0.19)

  1. acalculated by extracting diabetes, hypertension, and hyperlipidemia from among comorbidity components